There's limited availability, largely because of late FDA approval ...

Learn how mRNA and its lipid packaging change in the bloodstream, offering insights that could help researchers design better ...

Oct 13 (Reuters) - BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of ...

Skepticism about the government’s pandemic response is one thing. Writing off mRNA vaccine technology is another.

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna to $137 from $120 while maintaining a Neutral ...

Coca-Cola Co. (KO) and Visa Inc. (V) hit fresh 52-week highs on Thursday as positive company news lifted investor sentiment.

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

A new mRNA flu vaccine promises a closer match to circulating flu strains. But dysfunction at federal health agencies is ...

How delivery plays a new role as the key to success in mRNA application across therapeutic approaches For much of the past ...

Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...